^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-07260437

    i
    Other names: PF-07260437
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    CD3 agonist, B7-H4 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    C4431001: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=30, Terminated, Pfizer | Trial completion date: Jan 2024 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Oct 2023; Pfizer has made an internal business decision to not continue further development of PF-07260437. This decision was not due to major safety concerns or requests from any regulatory authorities.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression • VTCN1 overexpression
    |
    PF-07260437
    1year
    C4431001: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=25, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=100 --> 25 | Trial completion date: Sep 2025 --> Jan 2024 | Trial primary completion date: Sep 2025 --> Jan 2024
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression • VTCN1 overexpression
    |
    PF-07260437
    over1year
    C4431001: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Pfizer | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression • VTCN1 overexpression
    |
    PF-07260437
    3years
    C4431001: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Pfizer | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression
    |
    PF-07260437
    3years
    C4431001: A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Pfizer
    Clinical • New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    HER-2 negative • VTCN1 underexpression
    |
    PF-07260437